GLUE logo

MONTE ROSA THERAPEUTICS INC

GLUENASDAQ
πŸ† #2496 by market capUS Equity
$8.64β€”
Last available close Β· quote unavailable
πŸ””
Track GLUE
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 7.8%
14dβ–Ό 18.3%
30dβ–Ό 20.4%
ytdβ–Ό 44.9%
1yβ–Ό 39.2%
🏦Market Cap
$738M
Small Cap
πŸ“ˆRevenue Growth (YoY)
63.5%
High Growth
πŸ“ŠGross Margin
97.1%
High
πŸ’΅FCF Margin
-248.0%
Thin
βš–οΈP/S Ratio
10.5x
Elevated
Otter Score
60
Fair

Trading Snapshot

Day Range
β€”
52-Week Range
$8.48 – $25.77
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
85.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$124M
Last Q Revenue
$54M
P/E Ratio
-5.1
P/S Ratio
10.5x
EPS (TTM)
$-1.29
Dividend Yield
0.00%
Dilution (1yr)
+6.7%
GLUE logo

MONTE ROSA THERAPEUTICS INC

GLUE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$124Mβ–² +63.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.2%β–² +4.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$54Mβ–Ό βˆ’33.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$27Mβ–Ό βˆ’172.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
65.5Mβ–² +6.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$91Mβ–Ό βˆ’$91M YoY
StockOtter Β· stockotter.space

About MONTE ROSA THERAPEUTICS INC

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100
Analyst data unavailable.

Latest News & Updates

News unavailable.